

MONICA FORNIER, MD
PAMELA MUNSTER, MD
ANDREW D. SEIDMAN, MD
Breast Cancer Medicine Service
Memorial Sloan-Kettering
Cancer Center
New York, New York

Update on the Management of Advanced Breast Cancer

Breast cancer is the most frequently diagnosed cancer in American women, and the second most common cause of cancer death.[1] Over the past several decades, there has been a fairly steady increase in the incidence of the disease. Epidemiologic data from the United States analyzed between 1988 and 1990 indicate that the lifetime risk of developing breast cancer is 12.2%, or, stated in another way, one in eight women will develop the disease at some point during her life.[2]

Although approximately 80% of breast cancer patients present with disease limited to the breast and/or axillary lymph nodes, almost half of these patients later develop metastatic disease and eventually succumb to it. Metastatic breast cancer represents a historically incurable condition despite the judicious use of various hormonal manipulations, as well as surgical and radiotherapeutic interventions, and the application of active cytotoxic chemotherapeutic agents for hormone-refractory disease. For most patients with metastatic disease, treatment provides only temporary control of cancer growth. Outside of experimental protocols, the goals of management, therefore, are to palliate symptoms with as little treatment-related toxicity as possible and to extend the duration of high-quality life.

Metastatic breast cancer is moderately sensitive to chemotherapy, with 25% to 40% of patients achieving a partial or, less commonly, complete response to single-agent therapy; the duration of such responses averages 6 months.[3] Historically, the most commonly used cytotoxic agents in the management of metastatic breast cancer

ABSTRACT

Recent trials comparing single-agent vs combination therapy in metastatic breast cancer suggest that it may be time to reconsider the belief that combination chemotherapy is the gold standard of treatment. Based on the limited randomized trial data available to date, high-dose chemotherapy with stem-cell rescue should not be viewed as "state-of-the-art" treatment for metastatic disease and should be used only in the context of clinical trials. Recent trials have explored the optimal dosing and scheduling of the taxanes, as well as the possible role of these agents in combination regimens. Capecitabine (Xeloda), a new oral fluoropyrimidine, appears to be comparable in efficacy to CMF (cyclophosphamide, methotrexate, and fluorouracil), and preclinical data suggest possible synergy between this agent and the taxanes. Other promising agents under study include liposome-encapsulated doxorubicin (TLC D-99), an immunconjugate linking a chimeric human/mouse monoclonal antibody to doxorubicin molecules; MTA (LY231514), a multitargeted antifolate; and marimistat, a broad-spectrum matrix metalloproteinase inhibitor. Tamoxifen (Nolvadex) remains the most important hormonal agent, but new antiestrogens and selective estrogen receptor modulators (SERMs) may provide alternatives. The potential role of new aromatase inhibitors as first-line hormonal agents requires further study. Finally, the possible synergy between trastuzumab (Herceptin), a recombinant humanized monoclonal antibody to the HER-2/neu protein, and paclitaxel (Taxol) is being studied in two clinical trials.

have been cyclophosphamide (Cytosan, Neosar), methotrexate, fluorouracil, doxorubicin, and, more recently, the taxanes. When the disease progresses further, vinorelbine (Navelbine) and other vinca alkaloids, mitomycin (Mutamycin), mitoxantrone (Novantrone), gemcitabine (Gemzar), etoposide, and cisplatin (Platinol) represent some of the other frequently used cytotoxic drugs.

have been cyclophosphamide (Cytosan, Neosar), methotrexate, fluorouracil, doxorubicin, and, more recently, the taxanes. When the disease progresses further, vinorelbine (Navelbine) and other vinca alkaloids, mitomycin (Mutamycin), mitoxantrone (Novantrone), gemcitabine (Gemzar), etoposide, and cisplatin (Platinol) represent some of the other frequently used cytotoxic drugs.

Combination vs Single-Agent Chemotherapy

Combinations of two, three, or more chemotherapeutic agents are occasionally employed based on preclinical data suggesting improved antitumor activity (ie, additive or synergistic effects); many of these combinations are derived empirically, however. Although combination regimens may sometimes yield higher response proportions than single-agent therapy, this can occur at the cost of greater toxicity, perhaps resulting in an overall lower therapeutic index.[4] This issue was specifically addressed by two studies presented at the 34th annual meeting of the American Society of Clinical Oncology (ASCO) in 1998.

The first study, conducted by the Finnish Breast Cancer Group, randomized 303 breast cancer patients with distant metastases to one of two regimens: (1) single-agent chemotherapy with epirubicin (20 mg/m² weekly until disease progression or a cumulative dose of 1,000 mg/m²), followed by mitomycin (8 mg/m² every 4 weeks) as second-line therapy; or (2) the CEF polychemotherapy regimen, consisting of cyclophosphamide (500 mg/m²), epirubicin (60 mg/m²), and fluorouracil (500 mg/m²) every 3 weeks, followed by mitomycin (8 mg/m²) and vinblastine (6 mg/m²) every 4 weeks. Although responses to CEF tended to last modestly longer than responses to epirubicin alone (median duration, 12 vs 10.5 months; $P = .07$), no significant difference in time to progression ($P = .28$) or overall survival ($P = .65$) was found between the two arms.

Moreover, no difference in survival was seen when only the patients who received both the first- and second-line treatments were compared ($P = .96$), or when survival was calculated from the beginning of second-line therapy ($P = .56$). Single-agent therapy was also associated with less toxicity and better quality of life.[5]

The second report, presented by the International Taxotere 304 Study Group, described the results of a phase III study comparing single-agent docetaxel (Taxotere) therapy vs the combination of mitomycin and vinblastine in patients with metastatic breast cancer whose disease had progressed following an anthracycline-containing regimen. In this experience, single-agent

docetaxel therapy proved more effective than mitomycin plus vinblastine not only with respect to response rate and time to treatment failure, but gratifyingly, with regard to survival. Median survival duration was 10.5 months in the docetaxel group vs 8.5 months in the mitomycin-vinblastine group ($P = .0097$).[6]

In this context, the experience of Sledge and colleagues, reported at the 1997 ASCO meeting, should be considered.[7] In that study, Eastern Cooperative Oncology Group Study (E1193), single-agent therapy with docetaxel (Taxol) compared with the combination of doxorubicin and paclitaxel (Taxol) as first-line therapy in 739 patients with metastatic breast cancer. Patients receiving single-agent therapy were crossed over to the other agent at the time of disease progression.

Monotherapy with either docetaxel or paclitaxel had equivalent therapeutic activity; the combination of two drugs resulted in superior overall response rate and time to treatment failure. Despite this, combination therapy was not superior to sequential single-agent therapy with regard to overall survival and quality of life.

Taken together, these trials strongly prompt a reconsideration of the conventional wisdom that combination chemotherapy is the "gold standard" for the treatment of metastatic breast cancer.

Is More Better?

Ultimately, the treatment of metastatic breast cancer often represents an attempt to reach an equilibrium between the palliation conferred by response to therapy, on the one hand, and treatment-related toxicity, on the other. Thus, the issue of the value of intensification is of utmost importance since increased doses are commonly associated with greater toxicity.

Dose-Intensified Regimens

A trial of the Italian group Gruppo Oncologico Nord-Ovest (GONO) reported at ASCO 1998 by Lionetto is instructive in this regard. This randomized patients to receive either standard doses of CEF or the same regimen in an intensified manner with growth factor support; patients in

Table 1

Randomized Trials of High-Dose Chemotherapy/Autologous Stem-Cell Rescue (HDC/ASCR) for Metastatic Breast Cancer

Trial Number/ Sponsor(s)	HDC/ASCR Arm	Control Arm	Sample Size Accrual*	Target Completion Date
PBT-01 (Philadelphia Group, ECOG, SWOG, NCOG)	CMF/CAF x 4-6 → HDC/ASCR: CTCb	CMF/CAF x 4-6 → CMF x 2 yr	587 (standard dose) 516 (high dose)	Winter 1997
Duke University	AFM x 2-4 → HDC/ASCR: CBP	AFM x 2-4 → At relapse: CEF	80	
PEGASE	CEF x 4 → HDC/ASCR: CT	CEF x 4	180	
NCIC	A of Tx x 4 → HDC/ASCR: CMCcb x 2	Continue A (to dose limit) or Tx (9 cycles)	192	

Adapted from Zujewski J. *J Natl Cancer Inst* 90(3):200-209, 1998.

A = Adriamycin; AFM = Adriamycin, fluorouracil, methotrexate; CAF = Cyclophosphamide, Adriamycin, fluorouracil; CBP = Cyclophosphamide, BCNU (carbamustine), cisplatin; CEF = Cyclophosphamide, epirubicin, fluorouracil; CMF = Cyclophosphamide, methotrexate, fluorouracil; CMCcb = Cyclophosphamide, mitoxantrone, carboxiplatin; CT = Cyclophosphamide, thiotepa; CTCb = Cyclophosphamide, thiotepa, carboplatin; ECOG = Eastern Cooperative Oncology Group; NCOG = North Central Cancer Treatment Group; NCIC = National Cancer Institute of Canada; PBT = Philadelphia Transplant Group; PEGASE = Societe Francaise De Greffe Du Moelle; Federation National Du Lutte Contre Le Cancer; SWOG = Southwest Oncology Group; Tx = Taxol

* As of June 1, 1997

On the basis of the limited data available to date from randomized, prospective trials, high-dose chemotherapy cannot yet be considered "state-of-the-art" treatment for advanced breast cancer and should be offered only to patients in the setting of clinical trials. The final results of such large prospective trials are eagerly awaited (Table 1).

If multiagent chemotherapy and dose escalation prove to be suboptimal in conferring a consistent survival advantage in metastatic breast cancer, other strategies must be pursued. These include the development of newer active drugs, or the exploration of different alternatives, for example, biological therapies.

Taxanes and Beyond

The taxanes, ie, paclitaxel and docetaxel, are a relatively new addition to the chemotherapeutic arsenal against breast cancer. Their mechanism of action involves the formation of polymerized microtubules and their stabilization against the forces that lead to depolymerization. Proapoptotic effects, as well as antiangiogenic actions, may also be clinically relevant [14,15].

The determination of optimal dosing and scheduling of taxanes has been an important objective during their de-

Table 2

Randomized Trials of Single-Agent Taxanes in Metastatic Breast Cancer: Dose and Administration Schedule

Study	Dose (mg/m ²)	Administration Schedule (h)	Response Rate (%)	P Value
Paclitaxel				
BMS 048	175 mg/m ² 135 mg/m ²	3 h	29% 22%	.108
BMS 071	175 mg/m ²	3 h 24 h	29% 32%	NS
NSABP B-26	250 mg/m ²	3 h 24 h	40% 50%	.02
CALGB 9342	175 mg/m ² 210 mg/m ² 250 mg/m ²	3 h	21% 28% 22%	.64
MDACC	140 mg/m ² 250 mg/m ²	96 h 3 h	29% 23%	NS
Docetaxel				
RPR	100 mg/m ² 75 mg/m ²	1 h	NA	NA

BMS = Bristol-Myers Squibb; CALGB = Cancer and Leukemia Group B; MDACC = M. D. Anderson Cancer Center; NA = Not applicable; NS = Not significant; NSABP = National Adjuvant Surgical Breast and Bowel Project; RPR = Rhone-Poulenc Forter

velopment. While the clinical development of docetaxel has largely involved a single administration schedule (1-hour infusion) and a narrow dose range (60 to 100 mg/m²), the range of paclitaxel doses and schedules has been broader (varying from 80 to 250 mg/m² infused over 1 hour weekly to 3-, 24-, or even 96-hour infusions every 3 weeks).

Paclitaxel

• **Optimal Dose and Schedule**—Preclinical data have suggested that the duration of paclitaxel exposure may be more important than dose for the cytotoxic activity of this drug. Depending on the duration of exposure, cellular cytotoxicity can be achieved at relatively low concentrations of paclitaxel, on the order of 0.01 μM [16,17]. That duration of exposure can be an important element in the clinical activity of paclitaxel has also been demonstrated by the activity of prolonged 96-hour continuous infusions in some patients with metastatic breast cancer soon after their disease progressed during shorter infusions of the drug [18,19]. However, the administration of 96-hour continuous infusions of paclitaxel imposes a certain inconvenience for both the clinician and patient.

Many clinical trials have addressed the issue of both the optimal dosing and scheduling of the taxanes (Table 2). With regard to dosing, the results of a randomized trial of paclitaxel doses of 135 vs 175 mg/m² on a 3-hour schedule in pretreated women with metastatic breast cancer revealed no major differences in response rates (22% and 29%, respectively) or median survival durations (10.5 and 11.7 months, respectively). Progression-free survival was slightly longer with the 175-mg/m² dose than with the lower dose (4.2 vs 3 months; P = .02), however [20].

In the Cancer and Leukemia Group B (CALGB) trial 9342 reported at the 1998 ASCO meeting, 450 patients were randomized to receive 175-, 210-, or 250-mg/m² doses of paclitaxel on a 3-hour schedule. The three groups did not differ with respect to response rates or survival, but the higher doses were associated with greater toxicity, particularly peripheral neuropathy (26% rate of grade 3 events). These data provided little compelling evidence to support paclitaxel 3-hour infusion dosing of greater than 175 mg/m² in women

with metastatic breast cancer [21].

Another randomized clinical trial by M. D. Anderson Cancer Center detected no significant difference in objective responses or survival between paclitaxel at either 140 mg/m² 96-hour infusion or 250 mg/m² 3-hour infusion—the maximally tolerated doses at these schedules [22].

Two other trials have addressed optimal paclitaxel scheduling. The randomized Bristol-Myers Squibb 071 trial, in which women with metastatic breast cancer were treated with paclitaxel (175 mg/m²) infused over either 3 or 24 hours, allowing for inpatient dose escalation as tolerated, was conducted largely in Europe, Canada, and Israel. The two groups did not differ significantly with respect to response rates (29% and 32%, respectively).

Similar results were obtained by the National Adjuvant Breast and Bowel Project (NSABP) trial B-26. In this trial, response rates for paclitaxel (250 mg/m²) infused over either 3 or 24 hours were 40% and 50%, respectively, suggesting that the more myelosuppressive 24-hour schedule does not result in a significant improvement in outcome in the palliative setting [24]. The duration of patients with stage IIIB disease partly explains the higher response rates in the NSABP B-26 trial, as compared to the aforementioned studies.

• **Weekly Administration**—An alternative method to provide extended curative drug exposure is frequent, low-dose, low-toxicity drug administration, such as a weekly schedule. Weekly dosing of paclitaxel via a 1-hour infusion has been demonstrated to be a well-tolerated, feasible administration schedule. Weekly administration of paclitaxel at both dose-intense and dose-dense schedules also has a favorable toxicity profile, a remarkable degree of activity in patients with metastatic breast cancer.

In our experience at Memorial Sloan-Kettering Cancer Center, the overall response rate to a weekly administration schedule was 53% (95% confidence interval [CI], 34% to 72%), which compares favorably with the activity rates for 3-, 24-, and 96-hour regimens. In contrast to these other regimens, however, myelosuppression was insignificant with weekly paclitaxel, no febrile neutropenia was encountered, and

tients treated with the combination regimen had a 66% incidence of grade 3-4 neutropenia, vs a rate of 32% with paclitaxel alone, and two cases of congestive heart failure occurred with the combination, vs one case with paclitaxel alone. Analysis of survival awaits longer follow-up, but these data are certainly provocative, if not surprising in light of the ECOG 1193 results with paclitaxel plus doxorubicin.[7]

Docetaxel

Regarding docetaxel, Loeffler et al reported their experience with weekly infusions in stage IV breast cancer patients.[29] Doses were escalated in increments of 5 mg/m² from 30 to 45 mg/m² weekly × 6 with a 2-week break. The overall response rate was 50%, with 15% complete remissions and 35% partial remissions; 38% of patients had stable disease. Moreover, three out of five patients with a history of prior paclitaxel therapy responded to docetaxel. These investigators observed that weekly docetaxel has activity in chemotherapy-pre-treated breast cancer that is comparable to 100 mg/m² of docetaxel every 3 weeks, but with apparently less grade 3-4 leukopenia.

Another ASCO presentation by Sjöström et al focused on a phase III trial that compared docetaxel (100 mg/m²) every 3 weeks to methotrexate (200 mg/m²) plus fluorouracil (600 mg/m² on days 1 and 8) every 3 weeks (MF regimen) in 199 patients with anthracycline-resistant breast cancer.[30] The overall response rate (partial and complete) was 42% in the docetaxel arm and 19% in the MF arm (*P* < .001); median time to progression was 6 months in the docetaxel group and 3 months in the MF group (*P* = .006). These results thus demonstrated the superiority of single-agent docetaxel over MF for patients with anthracycline-resistant metastatic breast cancer.

Newer Agents

Capecitabine

Considering newer drugs for advanced breast cancer, one of the most interesting agents is capecitabine (Xeloda). Capecitabine is a novel, oral, selectively tumor-activated fluoropyrimidine carbamate that has shown promising activity in breast and colon cancers during phase I and II evaluations. This agent is sequentially




Figure 1: Chemical Structure and Mechanism of Action of Capecitabine—5'-DFCR = 5'-Deoxy-5-fluorocytidine; 5'-DFUR = 5'-Deoxy-5-fluorouridine; dThdPase = Thymidine phosphorylase; 5-FU = Fluorouracil

converted to fluorouracil by three enzymes located in the liver and within tumors, with the final conversion step to fluorouracil catalyzed by thymidine phosphorylase, which is found preferentially in breast cancer cells as compared to surrounding normal host tissues (Figure 1).

An abstract presented by Blum et al at the 1998 ASCO meeting described a phase II trial of twice-daily oral capecitabine (2,510 mg/m²/d) given for 2 weeks, followed by a 1-week rest period, and repeated in 3-week cycles, among patients with paclitaxel-refractory metastatic breast cancer.[31] A total of 163 patients were enrolled by 24 centers; patients had received at least two but no more than three prior chemotherapeutic regimens, one of which contained paclitaxel as treatment for metastatic disease.

The primary study end point was tumor response in patients with measurable disease. The response rate was 20%, median response duration was 8.1 months, and median survival was 12.8 months. Moreover, in patients with baseline pain > 20 mm on a visual analog scale, 47% showed a significant improvement in pain. Diarrhea (14%) and

hand-foot syndrome (10%) were the only treatment-related adverse events that occurred with a grade 3 or 4 intensity in ≥ 10% of patients. Alopecia did not occur and myelosuppression was minimal; there was no treatment-related mortality.

Given these data and the historical context of the use of continuous intravenous infusions of fluorouracil as a salvage therapy for metastatic breast cancer, capecitabine was approved by the FDA for use in patients with paclitaxel-refractory metastatic breast cancer in the spring of 1998. In summary, capecitabine can be considered an active drug in the treatment of paclitaxel-refractory advanced breast cancer with a relatively favorable toxicity profile.

• **Capecitabine vs Other Agents**—A second abstract reported at ASCO 1998 presented the results of a randomized phase II trial of capecitabine vs cyclophosphamide, methotrexate, and fluorouracil (CMF) as first-line chemotherapy for advanced breast cancer in women > 55 years old (median age in both groups, 69 years).[32] Capecitabine was given orally at a dosage of 2,510 mg/m² for

2 weeks, followed by 1 week of rest, and CMF was administered intravenously on day 1 every 21 to 28 days.

A total of 95 women were randomized. Response rates were 25% in the capecitabine-treated patients and 16% in the CMF recipients, and time to progression was 132 days with capecitabine vs 94 days with CMF.

Regarding toxicity, grade 3-4 clinical adverse events were reported by 44% of patients receiving capecitabine and 20% patients treated with CMF. The difference between the two groups was due primarily to hand-foot syndrome (16% vs 0%) and diarrhea (8% vs 3%). On the other hand, grade 3-4 hematologic toxicity occurred more frequently with CMF (47%) than with capecitabine (20%).

Overall, within the constraints imposed by relatively small sample sizes, it appears that home-based monotherapy with capecitabine appears to have at least comparable efficacy to CMF combination therapy in this older patient population.

Finally, in a multicenter trial presented by O'Reilly et al, the activity of capecitabine was compared to that of paclitaxel in patients with advanced breast cancer whose disease had progressed following prior anthracycline therapy.[33] In this study, two schedules of capecitabine were planned: (1) 2,510 mg/m²/d for 14 days, followed by 1 week of rest; or (2) a continuous daily schedule of 1,331 mg/m²/d. (The continuous arm of capecitabine was discontinued, however, after two patients were enrolled [personal communication, Dr. Fabio Benedetti, Roche, Inc., February 1999].) Paclitaxel was administered at a dosage of 175 mg/m² on day 1 of each 3-week cycle.

With 41 evaluable patients, the intermittent schedule of capecitabine yielded a 36% response rate, as compared with a 21% rate with paclitaxel. Median time to progression was 92 days on the intermittent capecitabine schedule and 95 days on paclitaxel. Grade 3-4 events were reported in 22% of patients treated with capecitabine and 58% given paclitaxel.

• **Capecitabine in Combination Regimens**—In a relevant preclinical Japanese study, the efficacy of capecitabine and fluorouracil in combination with other cytotoxic agents, including

taxanes, was evaluated in five xenograft models of human breast carcinoma cells.[34] While the combination of fluorouracil and taxanes demonstrated only additive effect, treatment with capecitabine and taxanes showed synergy and produced tumor regression in some xenograft models. In fact, the taxanes inhibited the tumor levels of thymidine phosphorylase by four- to eightfold within 10 days following the single administration, the treatment did not increase the mouse enzyme levels in normal tissues (intestine and liver), however, the tumor levels of thymidine phosphorylase correlate with in vivo susceptibility to capecitabine, it is possible that taxanes may enhance the efficacy of capecitabine by upregulating thymidine phosphorylase in human cancer cells.

Reinventing Old Drugs

The continued search for new agents for control of disease and reduction of symptoms in metastatic cancer has also led to the manipulation of the more conventional drugs to achieve equivalent or possibly superior activity with decreased toxicity.

Liposomal Doxorubicin

One promising agent in this category is liposome-encapsulated doxorubicin (TLC D-99). A phase III trial reported at ASCO 1998 evaluated its use against conventional doxorubicin, both at a dosage of 75 mg/m² every 3 weeks.[35] The trial randomized 69 patients who were stratified on the basis of prior exposure to doxorubicin. During the trial, patients underwent serial ventriculography to measure cumulative doses of 300, 400, and 500 mg/m² and then every cycle thereafter. Patients were removed from the trial if left-ventricular ejection fraction (LVEF) declined by ≥ 20% from baseline value (if this value was ≥ 50%) or by ≥ 10% from baseline (if < 50%) or if congestive heart failure developed.

Response rates were 33% in the TLC D-99 arm and 29% in the doxorubicin arm. Congestive heart failure developed in three patients (4%) treated with doxorubicin but in none of those given TLC D-99. Also, TLC D-99 generally produced less emesis, nausea, fever, and infection, suggesting that it may be as effective as free doxorubicin but perhaps safer.

reaction in 4%, and a grade 4 reaction in 15%. The skin rash problem was ameliorated with prophylactic dexamethasone.

Marimistat

Other agents under study include marimistat, a broad-spectrum matrix metalloproteinase inhibitor. This drug has already shown activity in numerous solid tumor models, including breast cancer, in which high levels of matrix metalloproteinases (enzymes instrumental in the growth and spread of malignant cells) are expressed. As reported at the 1998 ASCO meeting, an ongoing phase I study demonstrated the feasibility of using marimistat in conjunction with docetaxin and cyclophosphamide in patients with metastatic breast cancer.[38]

Hormonal Strategies

Endocrine therapy has been a critical component of the treatment of advanced breast cancer for over a century, since Beason published his observation of tumor response in women with metastatic breast cancer undergoing oophorectomy.[39] As hormonal interactions and their molecular mechanisms have become more well understood, more specific agents for hormonal therapy have been developed.

Over the last 2 decades, many new hormonal anticancer agents have been developed and introduced into clinical trials. However, despite this intense research, tamoxifen (Nolvadex) still remains the most important hormonal antitumor agent for breast cancer.

Tamoxifen

Tamoxifen is a synthetic antiestrogen that blocks estrogen binding to the estrogen receptor (ER). Although (unsuccessfully) designed as a contraceptive, tamoxifen's activity in metastatic breast cancer was recognized over 2 decades ago. Since then, many trials have confirmed the role of tamoxifen as a safe, effective antitumor agent. With an overall response rate of about 30% to 35% in unselected patients and a significantly higher response rate (60% to 75%) in patients with ER positive and progesterone receptor (PR) positive tumors, tamoxifen is as efficacious as many chemotherapy regimens.

A recent report of long-term follow-

up from earlier studies showed a median survival of 27.2 months and a median time to progression of 6.7 months when tamoxifen was used as initial hormonal therapy in women with ER/PR positive or unknown tumors.[40] However, less than 10% activity was noted among women with ER/PR negative tumors.

Several randomized studies demonstrated that tamoxifen doses higher than 20 mg/d do not confer further advantages.[41-43] The main side effects of tamoxifen include hot flashes, thromboembolic events (3.2% in women with metastatic cancer),[44] depression, a slight increase in endometrial cancer, and reported cases of corneal and retinal disease.

• **Use in Premenopausal Women**—Although the benefits of tamoxifen in postmenopausal women are unequivocal, its use in premenopausal women has been more controversial. First, a greater proportion of premenopausal metastatic breast cancer is ER/PR negative. Second, other methods, such as surgical- or radiation-induced ovarian ablation or hormonal blockade by luteinizing hormone-releasing hormone (LHRH) agonists have been favored by some experts. In addition, some authors have long recommended a combination of tamoxifen and either medical or surgical ovarian ablation.[45]

Tamoxifen and ovarian ablation have been compared in at least three randomized, albeit small, trials, and appear to be equally effective.[46-48] A meta-analysis including four trials comparing tamoxifen and ovarian ablation (by surgery or irradiation) in premenopausal women with ER positive tumors could not identify a superior regimen. Of note, however, were the observations that an initial response to either tamoxifen or ovarian ablation was predictive of a subsequent response to the other treatment,[49] and that failure to respond to tamoxifen did not preclude further response to oophorectomy in some women.[46]

A small Italian study compared surgical ovarian ablation to medical ovarian ablation (goserelin [Zoladex]), with or without tamoxifen, in a 2 × 2 design. This study found no clear survival advantage in any of the four groups, hence suggesting that combining tamoxifen with ovarian ablation does not add any

advantages. However, the patients who received concomitant tamoxifen and goserelin experienced more toxicity.[50]

• **Tamoxifen Resistance**—Unfortunately, breast cancer in most patients will eventually become resistant to tamoxifen. Tamoxifen resistance is not fully understood. None of the proposed mechanisms, such as the emergence of tamoxifen-dependent cell lines and loss or mutations of the ER, its functions, and interactions, appear to comprehensively explain resistance to tamoxifen.[51,52]

Other Antiestrogens

The significant activity and relatively modest toxicity of tamoxifen (ie, high therapeutic index) when compared with cytotoxic chemotherapy has led to an intensive search for other hormonal agents.

• **Toremifene (Fareston)**, an antiestrogen with properties similar to those of tamoxifen, was recently approved in the United States for the treatment of metastatic breast cancer. Large American and European randomized studies found no significant differences in the efficacy and safety of toremifene and tamoxifen when the two therapies were compared in postmenopausal women with ER positive or unknown tumors.[53-57] The reported response rates were between 29% to 50%. Toremifene doses higher than 60 mg/d did not offer any advantages over lower doses. A crossover trial demonstrated cross-resistance of the two drugs.[57]

• **Other novel antiestrogens** currently undergoing preclinical and clinical evaluation are droloxifene and the pure antiestrogen ICI 182780 (Faslodex). Droloxifene has been evaluated in phase II clinical trials.[58,59] Early clinical trials suggest that ICI 182780 has no adverse effects on the uterus, vagina, or brain, and that the drug is otherwise well tolerated.[60] More studies are needed to evaluate its efficacy.

• **Selective Estrogen Receptor Modulators**—The development of newer selective estrogen receptor modulators (SERMs) offers reason for optimism. Designed to be more selective and less toxic than older agents, the

SERMs have shown very exciting preclinical and clinical results. One SERM, raloxifene (Evista), approved for the treatment of osteoporosis in postmenopausal women, has also dramatically reduced the incidence of new breast cancers,[61] with relatively short follow-up. A "third-generation" SERM (LY353381) has entered phase II trials for the treatment of metastatic cancer after a phase I trial showed activity in women whose disease had progressed during tamoxifen therapy.

Aromatase Inhibitors

Aromatase inhibitors block the peripheral conversion of androstenedione to estrone. This effect is not specific to the ovaries, but rather, occurs in multiple organs, such as adipose tissue, muscle, and liver—the latter being important sites of estrogen production in postmenopausal women.

• **Aminoglutethimide**—The best known representative of this group is aminoglutethimide (Cytadren). When studied in women whose disease progressed while they were receiving tamoxifen, the patients with ER positive tumors had a response rate of 57%, as compared with a rate of 12% in those with ER negative tumors.[62] However, the relative lack of specificity of this agent, as well as bothersome side effects, such as adrenal suppression, skin rash, somnolence, dizziness, and gastrointestinal upset, have allowed newer more selective, less toxic aromatase inhibitors to take its place. Most of these agents are 100 to 1,000 more potent than aminoglutethimide. However, an evaluation of their efficacy as first-, second-, or third-line therapy in metastatic breast cancer awaits the completion or maturation of many ongoing studies (Table 3).

• **Anastrozole and Letrozole**—The most commonly used new aromatase agents are the triazole nonsteroidal agents anastrozole (Arimidex) and letrozole (Femara). These agents achieve a major reduction in estrogen levels without suppressing adrenal function. Within hours of administration, estradiol levels are significantly suppressed.

Anastrozole was compared with megestrol acetate (160 mg) as second-line therapy in advanced breast cancer in a three-arm randomized trial con-

ducted in Europe. Anastrozole was administered at doses of either 1 or 5 mg. Responses were seen in 34% of patients in the 1-mg group, 33.9% in the 5-mg group, and 32.8% in the 10-mg group, and 32.8% in the megestrol acetate-group.[63]

These findings were confirmed in an American study showing an objective response in 27% of women treated with 1 mg of anastrozole, 24% of those given 10 mg of the drug, and 24% of those who received megestrol acetate.[64,65] Although not significantly more active, anastrozole was better tolerated, with fewer cases of mild gastrointestinal disturbances. Also, once-daily dosing appears to be more convenient than the four daily doses of megestrol. No difference was noted between the two doses of anastrozole.

A randomized, double-blind compared two doses of letrozole (2.5 and 2.5 mg) with megestrol acetate (160 mg) as second-line therapy in 551 patients with locally advanced or metastatic breast cancer. Although no significant difference in time to progression between the 2.5-mg dose of letrozole and megestrol acetate was found, letrozole caused fewer adverse effects and was associated with better compliance.[66] The higher (2.5-mg) dose of letrozole yielded significantly better overall survival than the lower dose (0.5 mg).

• **Other nonsteroidal aromatase inhibitors** for the treatment of advanced breast cancer include fadrozole and vorozole. Fadrozole was compared with tamoxifen as first-line therapy in a randomized trial in 1,000 patients.[67] A large, randomized trial compared fadrozole and megestrol acetate as second-line therapy in the United States.[68] Neither trial showed a significant difference in efficacy, but the results suggested that fadrozole may be better tolerated than megestrol acetate. Fadrozole and tamoxifen do not appear to be mutually cross-resistant. In a comparing vorozole and megestrol acetate, vorozole was better tolerated and more efficacious.[69]

• **Steroidal Aromatase Inhibitors**—The steroidal aromatase inhibitors formestane and exemestane are presently being evaluated in clinical trials (Table 4). Formestane has been compared with tamoxifen but showed no significant difference in efficacy.[70]

Table 3

Selected Trials of Endocrine Therapy in Advanced Breast Cancer

Study	Study Design	Number of Patients	Response Rate (%)	Median Duration of Response	P Value
Smith et al[84]	AG vs tamoxifen	117	30% vs 30%	15 mo vs 15+ mo	NS
Ingle et al[85]	DES vs tamoxifen	143	41% vs 33%	4.7 mo vs 5.9 mo	NS
Muss et al[86]	MPA vs tamoxifen	182	17% vs 43%	6.3 mo vs 5.5 mo	NS
Muss et al[87]	MA vs tamoxifen	138	28% vs 31%		NS
Peraz Camion et al[88]	Formestane vs tamoxifen	409	33% vs 37%	15 mo vs 20 mo	NS
Thurlimann et al[67]	Fadrozole vs tamoxifen	212	20% vs 27%	6.1 mo vs 8.5 mo	NS
Dombrowsky et al[66]	Letrozole (2.5 mg) Letrozole (0.5 mg) MA (160 mg)	551	24% 16% 13%		NS
Budzar et al[64, 65]	Anastrozole (1 mg) Anastrozole (10 mg) MA (160 mg)	764	27% 24% 30%[64]	56.1%[64] 54.6% 46.3%[65]	NS
Buchanan et al[47]	OvAbi vs tamoxifen	122	24% vs 21%	7 mo vs 20 mo	NS
Pyronen et al[54]	Toremifene vs tamoxifen	415	31.3% vs 37.3%	7.3 mo vs 10.2 mo	NS
Goss et al[69]	Vorzole vs MA	452	10.5% vs 7.6%	18.2 mo vs 12.5 mo	NS

AG = Aminoglutethimide; DES = Diethylstilbestrol; MA = Megestrol acetate; MPA = Medroxyprogesterone; NS = Not significant; OvAbi = Ovarian ablation

*2-Year overall survival rate

transducer of mitotic stimuli.[73,74]

Like the epidermal growth-factor receptor, HER-2/neu receptor expression appears to reflect increased proliferative activity in tumors. Amplification of the HER-2/neu gene and/or overexpression of its messenger RNA (mRNA) and protein have been identified in many human cancers and are seen in 25% to 30% of breast cancers,[75] suggesting that these abnormalities may contribute to malignant transformation and tumorigenesis.[76] In fact, HER-2 overexpression has been correlated with poor outcome in patients with breast cancer.[77,78]

Trastuzumab

A recombinant humanized monoclonal antibody that binds specifically to the extracellular domain of p185^{HER2}, (huMab HER2) trastuzumab (Herceptin) has demonstrated antitumor activity against HER-2/neu-overexpressing metastatic breast cancer in phase II and III trials.[79-81] Its activity may be explained by at least three

mechanisms of action: The antibody may (1) antagonize the function of the growth-signaling properties of the HER-2 system; (2) signal immune cells to attack and kill tumor cells; and (3) increase chemotherapy-induced cytotoxicity.

• **Single-Agent Trastuzumab**—Our experience at Memorial Sloan-Kettering Cancer Center with trastuzumab was reported in 1996. We treated 46 metastatic breast cancer patients whose tumors overexpressed HER-2 (as demonstrated by immunohistochemical analysis using the murine monoclonal antibody 4D5) with trastuzumab at an initial loading dose of 250 mg and subsequent weekly doses of 100 mg. These patients had received a median of three prior chemotherapy regimens.

All toxicities were minimal, and no human antihuman antibodies (HABA) against trastuzumab were detected in any patient. An overall response rate of 11.6% was observed, including one

complete and four partial remissions. As of this writing, one patient remains in complete remission after > 2.5 years of trastuzumab therapy.

This observation was expanded and confirmed in a multinational trial reported at ASCO 1998 by Cobleigh et al, which evaluated the efficacy and safety of trastuzumab given as a single agent in 222 women with HER-2-overexpressing metastatic breast cancer.[80] Trastuzumab was delivered at an initial loading dose of 4 mg/kg and subsequently at a weekly dose of 2 mg/kg. All patients had been pretreated with chemotherapy; 69% had received adjuvant therapy, 32% had had one regimen for metastatic disease, 68% had had two regimens, and 25% had received prior high-dose chemotherapy.

Address all correspondence to:
Andrew D. Seidman, MD
Memorial Sloan-Kettering Cancer Center
1275 York Avenue
New York, NY 10021

Table 4

Ongoing Trials of Endocrine Therapy in Metastatic Breast Cancer

Study	Trial Type	Design
RPCI-DS-97-29, NCI-G98-1412	Phase III, double-blind, randomized	ICI 162780 vs anastrozole in postmenopausal women with advanced breast cancer
Novartis 2026701025, NCI-V98-1388	Phase III, double-blind, randomized	Letrozole vs tamoxifen in postmenopausal women with stage IIB, metastatic or recurrent breast cancer
SB-2230307010	Phase III, randomized	Idoxifene vs tamoxifen in postmenopausal women with metastatic breast cancer
SWOG-9630	Phase III, randomized	Medroxyprogesterone vs tamoxifen in breast cancer patients with breast cancer
MSKCC-98038, NCI-G98-1451	Phase II, double-blind, randomized	SERM III LY353381 20 mg vs tamoxifen
SVMC-V89-0296, NCI-V89-0296	Phase III	High-dose megestrol vs tamoxifen in women with metastatic breast cancer, endometrial cancer, or mesothelioma
EORTC-10951	Phase II	Exemestane vs tamoxifen in women with locally recurrent or metastatic breast cancer
NCI-95-C-00808, NCI-195-0090N, NYU-9440	Phase I	9-cis-retinoic acid and tamoxifen in women with advanced breast cancer

EORTC = European Organization for Research and Treatment of Cancer; MSKCC = Memorial Sloan-Kettering Cancer Center; NCI = National Cancer Institute; NYU = New York University; RPCI-DS = Roswell Park Cancer Institute; SB = SmithKline Beecham; SVMC = Saint Vincent Medical Center; SWOG = Southwest Oncology Group; SERM = Selective estrogen receptor modulator

*Trial of two dose levels in women with locally advanced metastatic breast cancer

After a median follow-up of 11 months, the investigator-determined overall response rate was 21% (95% CI, 16% to 27%), with a 4% rate of complete remissions. The independent response evaluation committee-determined response rate was 15% (95% CI, 10% to 20%). The median response duration was 8.4 months. Reduction in cardiac ejection fraction was observed in nine patients, of whom six were symptomatic; all either had received prior anthracycline therapy or had a significant cardiac history at entry.

In summary, trastuzumab has a favorable toxicity profile, is active as a single agent in women with HER-2-overexpressing metastatic breast cancer, and induces durable objective tumor responses.

• **Trastuzumab Combined Chemotherapy**—Slamon et al published the results of a phase III trial of trastuzumab in 469 patients with HER-2-overexpressing metastatic breast cancer at the 1998 ASCO meeting.[81] This trial was based on observations in clinical models of synergy between trastuzumab and some chemotherapy agents, in particular, doxorubicin and paclitaxel. For example, Baselga demonstrated marked synergistic tumor activity for paclitaxel plus trastuzumab against HER-2-overexpressing mammary carcinoma cells.[82]

In the phase III trial, patients received either doxorubicin (60 mg/m²) plus cyclophosphamide (600 mg/m²) they had not received doxorubicin in the adjuvant setting, or paclitaxel

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.